Group 1: Financial Performance - Merck expects sales for 2026 to be between $65.5 billion and $67 billion, with adjusted earnings per share projected at $5.00 to $5.15, which is below Wall Street expectations due to one-time costs from the acquisition of Cidara Therapeutics [2] Group 2: Company Status - Keytruda's key patent is expected to gradually expire starting in 2028, with its growth showing signs of slowing down, as evidenced by 2025 sales of $31.7 billion, reflecting a 7% year-over-year increase [3] - Merck is in talks to acquire biotechnology company Revolution Medicines for a potential price of $28 billion to $32 billion, aiming to enhance its oncology pipeline with the experimental drug Daraxonrasib [4] - Sales of the HPV vaccine Gardasil declined by 39% year-over-year to $5.233 billion in 2025, impacted by decreased demand in China and updated vaccination guidelines in the U.S., necessitating ongoing monitoring of its recovery [6] Group 3: Product Development Progress - The pulmonary arterial hypertension drug Winrevair (sotatercept) achieved sales of $1.443 billion in 2025 and is expected to gain FDA approval for new indications in 2026, positioning it as a key product [5] - Oral PCSK9 inhibitor Enlicitide and other cardiovascular products are in late-stage development and may represent new growth opportunities [5]